{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T14:14:31Z","timestamp":1788963271233,"version":"build-2803163510"},"reference-count":28,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,26]],"date-time":"2021-04-26T00:00:00Z","timestamp":1619395200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","heartrhythmjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heart Rhythm"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.hrthm.2021.04.007","type":"journal-article","created":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T22:20:04Z","timestamp":1618352404000},"page":"1416-1422","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Flecainide-induced QRS complex widening correlates with negative inotropy"],"prefix":"10.1016","volume":"18","author":[{"given":"Ana B.","family":"Rab\u00ealo Evangelista","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe R.","family":"Monteiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce D.","family":"Nearing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luiz","family":"Belardinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard L.","family":"Verrier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.hrthm.2021.04.007_bib1","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/nrcardio.2014.118","article-title":"Global epidemiology of atrial fibrillation","volume":"11","author":"Rahman","year":"2014","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.hrthm.2021.04.007_bib2","doi-asserted-by":"crossref","first-page":"ITC33","DOI":"10.7326\/AITC201703070","article-title":"In the clinic: atrial fibrillation","volume":"166","author":"Zimetbaum","year":"2016","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.hrthm.2021.04.007_bib3","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1056\/NEJMoa041233","article-title":"Outpatient treatment of recent onset atrial fibrillation with the \u201cpill-in-the-pocket\u201d approach","volume":"351","author":"Alboni","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hrthm.2021.04.007_bib4","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1136\/hrt.2009.187963","article-title":"Intravenous administration of flecainide or propafenone in patients with recent-onset atrial fibrillation does not predict adverse effects during \u201cpill-in-the-pocket\u201d treatment","volume":"96","author":"Alboni","year":"2010","journal-title":"Heart"},{"key":"10.1016\/j.hrthm.2021.04.007_bib5","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.hrthm.2017.10.002","article-title":"Clinical effectiveness of a systematic \"pill-in-the-pocket\" approach for the management of paroxysmal atrial fibrillation","volume":"15","author":"Andrade","year":"2018","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.hrthm.2021.04.007_bib6","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1378\/chest.103.4.1068","article-title":"Effects of flecainide and propafenone on systolic performance in subjects with normal cardiac function","volume":"103","author":"Santinelli","year":"1993","journal-title":"Chest"},{"key":"10.1016\/j.hrthm.2021.04.007_bib7","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1097\/FJC.0000000000000804","article-title":"Pulmonary delivery of antiarrhythmic drugs for rapid conversion of new-onset atrial fibrillation","volume":"75","author":"Verrier","year":"2020","journal-title":"J Cardiovasc Pharmacol"},{"issue":"Suppl 3","key":"10.1016\/j.hrthm.2021.04.007_bib8","first-page":"A15742","volume":"142","author":"Crijns","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.hrthm.2021.04.007_bib9","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.ijcard.2018.09.029","article-title":"Optimizing flecainide plasma concentration profile for atrial fibrillation conversion while minimizing adverse ventricular effects by rapid, low-dose intratracheal or intravenous administration","volume":"274","author":"Marum","year":"2019","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.hrthm.2021.04.007_bib10","doi-asserted-by":"crossref","first-page":"e101","DOI":"10.1016\/j.jacc.2010.09.013","article-title":"2011 ACCF\/AHA\/HRS focused updates incorporated into the ACC\/AHA\/ESC 2006 guidelines for the management of patients with atrial fibrillation","volume":"57","author":"Fuster","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hrthm.2021.04.007_bib11","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"ESC Scientific Document Group. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS)","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hrthm.2021.04.007_bib12","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1016\/j.hrthm.2018.06.036","article-title":"Accelerated conversion of atrial fibrillation in normal sinus rhythm by pulmonary delivery of flecainide acetate in a porcine model","volume":"15","author":"Verrier","year":"2018","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.hrthm.2021.04.007_bib13","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/0002-8703(85)90413-2","article-title":"Hemodynamic effects of intravenous flecainide relative to the level of ventricular function in patients with coronary artery disease","volume":"109","author":"Josephson","year":"1985","journal-title":"Am Heart J"},{"key":"10.1016\/j.hrthm.2021.04.007_bib14","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1093\/oxfordjournals.eurheartj.a061918","article-title":"Comparative haemodynamic effects of intravenous flecainide in patients with and without heart failure and with and without beta-blocker therapy","volume":"6","author":"Legrand","year":"1985","journal-title":"Eur Heart J"},{"key":"10.1016\/j.hrthm.2021.04.007_bib15","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1111\/jce.13708","article-title":"Pulmonary delivery of flecainide causes a rate-dependent predominant effect on atrial compared to ventricular depolarization duration revealed by intracardiac recordings in an intact porcine model","volume":"29","author":"De Antonio","year":"2018","journal-title":"J Cardiovasc Electrophysiol"},{"key":"10.1016\/j.hrthm.2021.04.007_bib16","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1085\/jgp.85.3.476","article-title":"Na\/Ca exchange in the intact cardiac cell","volume":"85","author":"Sheu","year":"1985","journal-title":"J Gen Physiol"},{"issue":"3 Pt 1","key":"10.1016\/j.hrthm.2021.04.007_bib17","doi-asserted-by":"crossref","first-page":"C549","DOI":"10.1152\/ajpcell.1989.256.3.C549","article-title":"Inhibition of ICa in single frog cardiac cells by quinidine, flecainide, ethmozin, and ethacizin","volume":"256","author":"Scamps","year":"1989","journal-title":"Am J Physiol"},{"key":"10.1016\/j.hrthm.2021.04.007_bib18","doi-asserted-by":"crossref","first-page":"41B","DOI":"10.1016\/0002-9149(84)90501-0","article-title":"Metabolism of flecainide","volume":"53","author":"Conard","year":"1984","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.hrthm.2021.04.007_bib19","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0378-4347(00)00343-1","article-title":"Therapeutic drug monitoring of flecainide in serum using high-performance liquid chromatography and electrospray mass spectrometry","volume":"746","author":"Breindahl","year":"2000","journal-title":"J Chromatogr B Biomed Sci Appl"},{"key":"10.1016\/j.hrthm.2021.04.007_bib20","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/FJC.0000000000000020","article-title":"Electrophysiological and hemodynamic effects of vernakalant and flecainide during cardiac resynchronization in dyssynchronous canine hearts","volume":"63","author":"Van Middendorp","year":"2014","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.hrthm.2021.04.007_bib21","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s00228-004-0831-3","article-title":"Absorption kinetics and pharmacodynamics of two oral dosage forms of flecainide in patients with an episode of paroxysmal atrial fibrillation","volume":"60","author":"Deneer","year":"2004","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.hrthm.2021.04.007_bib22","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/jce.14289","article-title":"Multimodal mechanisms and enhanced efficiency of atrial fibrillation cardioversion by pulmonary delivery of a novel flecainide formulation","volume":"31","author":"Tessarolo Silva","year":"2020","journal-title":"J Cardiovasc Electrophysiol"},{"key":"10.1016\/j.hrthm.2021.04.007_bib23","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1152\/physrev.1989.69.4.1049","article-title":"Electrophysiological mechanisms of ventricular arrhythmias resulting from myocardial ischemia and infarction","volume":"69","author":"Janse","year":"1989","journal-title":"Physiol Rev"},{"key":"10.1016\/j.hrthm.2021.04.007_bib24","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.vascn.2013.10.001","article-title":"Pharmacokinetic-pharmacodynamic modeling of QRS-prolongation by flecainide: heart rate-dependent effects during sinus rhythm in conscious telemetered dogs","volume":"69","author":"S\u00e4llstr\u00f6m","year":"2014","journal-title":"J Pharmacol Toxicol Methods"},{"key":"10.1016\/j.hrthm.2021.04.007_bib25","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1365-2125.1983.tb02143.x","article-title":"The haemodynamic effect of intravenous flecainide acetate in patients with coronary artery disease","volume":"16","author":"Serruys","year":"1983","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.hrthm.2021.04.007_bib26","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/clpt.1985.37","article-title":"Effect of flecainide on cardiac output","volume":"37","author":"Muhiddin","year":"1985","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.hrthm.2021.04.007_bib27","first-page":"643","article-title":"Plasma concentrations of flecainide acetate, a new antiarrhythmic agent, in humans","volume":"6","author":"Conard","year":"1984","journal-title":"Clin Ther"},{"key":"10.1016\/j.hrthm.2021.04.007_bib28","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1093\/europace\/euq382","article-title":"Twenty-five years in the making: flecainide is safe and effective for the management of atrial fibrillation","volume":"13","author":"Aliot","year":"2011","journal-title":"Europace"}],"container-title":["Heart Rhythm"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1547527121003301?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1547527121003301?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T06:53:20Z","timestamp":1761548000000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1547527121003301"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":28,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["S1547527121003301"],"URL":"https:\/\/doi.org\/10.1016\/j.hrthm.2021.04.007","relation":{},"ISSN":["1547-5271"],"issn-type":[{"value":"1547-5271","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Flecainide-induced QRS complex widening correlates with negative inotropy","name":"articletitle","label":"Article Title"},{"value":"Heart Rhythm","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hrthm.2021.04.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Heart Rhythm Society.","name":"copyright","label":"Copyright"}]}}